News FDA fast-tracks NeuroVive's traumatic brain injury drug The FDA has fast-tracked a drug to treat severe traumatic brain injury from Swedish pharma NeuroVive, hastening its development and review.
News Sandoz separates from Novartis, valued at just over $11bn Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange.
R&D Turning drug development on its head Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho